• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Kenvue Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    3/5/25 8:06:54 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary
    Get the next $KVUE alert in real time by email
    kvue-20250305
    0001944048false00019440482025-03-052025-03-05

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
    FORM 8-K
    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934
    Date of Report (Date of earliest event reported): March 5, 2025
    Kenvue Inc.
     (Exact name of registrant as specified in its charter)
    Delaware001-4169788-1032011
    (State or other jurisdiction
     of incorporation)
    (Commission
    File Number)
    (IRS Employer
    Identification No.)
    199 Grandview Road
    Skillman, New Jersey
    08558
    (Address of principal executive offices)(Zip Code)
    Registrant's telephone number, including area code: (908)-874-1200
    Not applicable
    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
    ☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.01 par value per shareKVUENew York Stock Exchange
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 1.01 Entry into a Material Definitive Agreement.
    On March 5, 2025, Kenvue Inc. (the “Company”) entered into a cooperation agreement (the “Agreement”) with Starboard Value and Opportunity Master Fund Ltd and certain of its affiliates (collectively, “Starboard”).
    Pursuant to the Agreement, the Company (i) in accordance with Section 2 of Article Five of the Company’s Amended and Restated Certificate of Incorporation, adopted as of May 3, 2023, agreed to temporarily increase the size of the Board of Directors of the Company (the “Board”) from eleven to fourteen directors; (ii) agreed to appoint each of Sarah Hofstetter, Erica Lilith Mann and Jeffrey C. Smith (the “Starboard Appointee” and, together with Ms. Hofstetter and Ms. Mann, the “New Appointees”) as directors of the Company effective immediately, with each of their terms expiring at the 2025 annual meeting of the Company’s stockholders (the “2025 Annual Meeting”); and (iii) agreed to nominate each of the New Appointees and ten incumbent directors of the Company for election to the Board at the 2025 Annual Meeting. Following the 2025 Annual Meeting until the expiration of the Standstill Period (as defined below), the Company may not increase the size of the Board to more than thirteen directors without Starboard’s prior written consent.
    With respect to the 2025 Annual Meeting, Starboard agreed to, among other things, (i) withdraw its letter to the Company dated December 10, 2024, nominating a slate of director candidates to be elected to the Board at the 2025 Annual Meeting, and each director nomination set forth therein, and (ii) vote, subject to certain conditions, all shares of the Company’s common stock beneficially owned by Starboard in favor of the Company’s director nominees and in accordance with the Board’s recommendations on all other proposals, subject to certain limited exceptions.
    Starboard also agreed to certain customary standstill provisions, effective as of the date of the Agreement through the earlier of (x) fifteen business days prior to the deadline for the submission of stockholder nominations for the 2026 annual meeting of the Company’s stockholders pursuant to the Company’s Amended and Restated Bylaws or (y) the date that is ninety days prior to the first anniversary of the 2025 Annual Meeting (the “Standstill Period”).
    The Agreement also includes provisions regarding committee membership of the New Appointees, procedures for determining any replacements for the New Appointees, non-disparagement and expense reimbursement, among other matters.
    The foregoing description of the terms and conditions of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached as Exhibit 10.1 hereto and is incorporated herein by reference.
    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
    The description of the matters included under Item 1.01 are incorporated into this Item 5.02 by reference.
    Each of the New Appointees will receive the standard director compensation that the Company provides to its non-employee directors as described in the Company’s Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 10, 2024.
    The Starboard Appointee has been appointed to the Compensation & Human Capital Committee of the Board. Ms. Hofstetter has been appointed to the Audit Committee of the Board. Ms. Mann has been appointed to the Nominating, Governance & Sustainability Committee of the Board.
    Ms. Hofstetter is the president of Profitero, Ltd., a subsidiary of Publicis Groupe S.A. The Company paid Profitero, Ltd. approximately $1.2 million in 2024 for advertising and marketing services. These services were provided to the Company on an arms’ length basis, and Ms. Hofstetter has no role in the Company’s decision making with respect to which firms to utilize for these services.
    As of the date hereof, other than as set forth above, there are no transactions between any of the New Appointees and the Company that would be reportable under Item 404(a) of Regulation S-K.
    Item 8.01 Other Events.
    On March 5, 2025, the Company and Starboard jointly issued a press release announcing the appointment of the New Appointees and the Agreement. A copy of the press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.




    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.
    Exhibit Number
    Exhibit Description
    10.1
    Cooperation Agreement dated March 5, 2025, by and between Kenvue Inc. and the entities and natural person listed on the signature pages attached thereto
    99.1
    Press Release dated March 5, 2025
    104
    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL







    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    KENVUE INC.
    Date: March 5, 2025By:/s/ Edward J. Reed
      Name:
    Title:
    Edward J. Reed
    Vice President, Corporate Secretary

    Get the next $KVUE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVUE

    DatePrice TargetRatingAnalyst
    1/30/2026$18.00Buy → Hold
    Jefferies
    10/29/2025$15.00Buy → Hold
    Canaccord Genuity
    9/26/2025$22.00Neutral → Buy
    Rothschild & Co Redburn
    4/10/2025$23.50Neutral
    Redburn Atlantic
    3/24/2025$25.00In-line
    Evercore ISI
    1/6/2025$21.00 → $26.00Neutral → Overweight
    Piper Sandler
    12/12/2024$25.00 → $24.00Buy → Hold
    Deutsche Bank
    9/24/2024$27.00Buy
    Jefferies
    More analyst ratings

    $KVUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kenvue Reports Fourth Quarter and Full Year 2025 Results

    Q4 Net Sales 3.2%; Organic Sales1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS1 was $0.27 FY'25 Net Sales (2.1)%; Organic Sales (2.2)% FY'25 Diluted EPS was $0.76; Adjusted Diluted EPS was $1.08 Kenvue Inc. (NYSE:KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. "We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales," said Kirk Perry, Chief Executive Officer. "As we look to 2026, we remain focused on continuing to enhance our performance, while progr

    2/17/26 4:45:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue

    Key Milestone in Creating a Global Health and Wellness Leader Transaction Expected to Close in the Second Half of 2026 DALLAS and SUMMIT, N.J., Jan. 29, 2026 /PRNewswire/ -- Kimberly-Clark Corporation (NASDAQ:KMB) and Kenvue Inc. (NYSE:KVUE) today announced that Kimberly-Clark and Kenvue shareholders voted overwhelmingly to approve all of the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue at their respective Special Meetings of Stockholders held today. "We are grateful to Kimberly-Clark shareholders who voted resoundingly in support of our combina

    1/29/26 9:27:00 AM ET
    $KMB
    $KVUE
    Containers/Packaging
    Consumer Discretionary
    Specialty Chemicals

    $KVUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kenvue downgraded by Jefferies with a new price target

    Jefferies downgraded Kenvue from Buy to Hold and set a new price target of $18.00

    1/30/26 6:43:10 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Kenvue from Buy to Hold and set a new price target of $15.00

    10/29/25 7:19:36 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Kenvue from Neutral to Buy and set a new price target of $22.00

    9/26/25 8:00:14 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Jeffrey C bought $110,986,526 worth of shares (6,377,694 units at $17.40) (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    12/15/25 4:00:25 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    SEC Filings

    View All

    SEC Form 10-K filed by Kenvue Inc.

    10-K - Kenvue Inc. (0001944048) (Filer)

    2/20/26 7:13:06 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

    8-K - Kenvue Inc. (0001944048) (Filer)

    2/17/26 4:46:12 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Kenvue Inc.

    SCHEDULE 13G/A - Kenvue Inc. (0001944048) (Subject)

    2/17/26 10:26:21 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Officer Alvarado Luani converted options into 15,942 shares and covered exercise/tax liability with 5,468 shares, increasing direct ownership by 22% to 57,076 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    2/18/26 8:35:24 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Chief Operations Officer Stevens Meredith converted options into 28,040 shares and covered exercise/tax liability with 8,031 shares, increasing direct ownership by 30% to 86,046 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    2/18/26 8:35:30 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    VP & Chief Accounting Officer Howlett Heather converted options into 13,571 shares and covered exercise/tax liability with 4,649 shares, increasing direct ownership by 42% to 30,190 units (SEC Form 4)

    4 - Kenvue Inc. (0001944048) (Issuer)

    2/18/26 8:35:14 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/14/24 1:22:40 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    11/12/24 10:32:12 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Kenvue Inc.

    SC 13G/A - Kenvue Inc. (0001944048) (Subject)

    10/16/24 10:07:52 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Leadership Updates

    Live Leadership Updates

    View All

    Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value

    Appoints Current Kenvue Director and Proven CPG and Technology Company Leader, Kirk Perry, as Interim CEO, Effective Immediately Announces Ongoing Review of Strategic Alternatives Reports Select Preliminary Second Quarter 2025 Financial Results Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors is implementing a set of actions to enable the Company to unlock shareholder value and reach its full potential. The Board has made a Chief Executive Officer transition and is advancing an ongoing comprehensive review of strategic alternatives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714520711/en/Kirk

    7/14/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Debuts on Fortune 500 List

    Kenvue Inc. (NYSE:KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. "Being named to the Fortune 500 list marks a significant milestone for Kenvue," said Thibaut Mongon, Chief Executive Officer. "Recognitions like this validate the hard work and dedication of our K

    6/2/25 6:15:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Announces Chief Financial Officer Transition

    Amit Banati, 30-Year Consumer Products Company Finance and Operations Veteran, Appointed CFO Succeeds Paul Ruh, Effective May 12, 2025 Kenvue Inc. (NYSE:KVUE), today announced the appointment of Amit Banati as the Company's Chief Financial Officer, effective May 12, 2025. He will be responsible for overseeing the Finance and Strategy functions, supporting initiatives aimed at accelerating profitable growth and delivering value to shareholders. Following a thorough and thoughtful search process, Mr. Banati will succeed Paul Ruh, who will remain with the Company for a brief period to help ensure a smooth transition. Mr. Banati is a 30-year consumer products company finance and operation

    5/8/25 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    $KVUE
    Financials

    Live finance-specific insights

    View All

    Kenvue Reports Fourth Quarter and Full Year 2025 Results

    Q4 Net Sales 3.2%; Organic Sales1 1.2% Q4 Diluted EPS was $0.17; Adjusted Diluted EPS1 was $0.27 FY'25 Net Sales (2.1)%; Organic Sales (2.2)% FY'25 Diluted EPS was $0.76; Adjusted Diluted EPS was $1.08 Kenvue Inc. (NYSE:KVUE) today announced financial results for the fiscal fourth quarter and full year ended December 28, 2025. "We ended 2025 with stronger top- and bottom-line performance in the fourth quarter, which reflected both disciplined execution against our strategic priorities, as well as a more favorable year-ago comparison on sales," said Kirk Perry, Chief Executive Officer. "As we look to 2026, we remain focused on continuing to enhance our performance, while progr

    2/17/26 4:45:00 PM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

    Kenvue Inc. (NYSE:KVUE) will announce its fourth quarter and full year 2025 financial results after market close on February 17, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results. The press release will be available on the company's website at investors.kenvue.com. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue,

    2/4/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary

    Kenvue Declares Quarterly Cash Dividend

    Kenvue Inc. (NYSE:KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on February 25, 2026, to shareholders of record as of the close of business on February 11, 2026. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that po

    1/28/26 6:45:00 AM ET
    $KVUE
    Specialty Chemicals
    Consumer Discretionary